沃森生物高管薪酬不走审议程序，监管出手！

Core Viewpoint - Watson Bio has received administrative regulatory measures from the Yunnan Securities Regulatory Bureau due to non-compliance with regulations regarding the approval of executive compensation for 2023 and 2024 [1][2] Group 1: Regulatory Actions - Watson Bio was found to have failed to submit the compensation matters for directors and senior management for 2023 and 2024 to the shareholders' meeting and board of directors as required [1] - The company has been ordered to rectify the situation and this will be recorded in the securities and futures market integrity file [1] - On December 19, Watson Bio received a regulatory letter from the Shenzhen Stock Exchange due to the same issues [1] Group 2: Financial Performance - Watson Bio's total compensation for directors, supervisors, and senior management for 2023 and 2024 amounts to 44.22 million yuan and 24.71 million yuan, respectively [1] - The company has faced declining performance, with revenue and net profit attributable to shareholders decreasing for two consecutive years [2] - In the first three quarters of 2025, Watson Bio reported revenue of 1.719 billion yuan, a year-on-year decrease of 19.73%, and a net profit of 163 million yuan, down 36.24% year-on-year [2] Group 3: Market Performance - As of December 19, Watson Bio's stock closed at 11.3 yuan per share, with a total market capitalization of 18.07 billion yuan [3] - The stock has experienced a year-to-date decline of 6.38% [3]